Active Surveillance for Low Risk Prostate Cancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexMale
Age50-75
SponsorI.M. Sechenov First Moscow State Medical University
About this trial
An active surveillance protocol for patients diagnosed low-risk prostate cancer will be held. We plan to use PSA (prostate-specific antigen) testing, DRE (digital rectal examination), TRUS (transrectal ultrasound), MRI (magnetic resonance imaging) and follow-up biopsies to monitor patients and detect cancer progression in time.
Eligibility criteria
Qualifiers
prostate adenocarcinoma verified by at least 12 core biopsy
patient must understand the sense of research, agree to participate and sign a form of agreement
low oncological risk according to EAU (European Association of Urology) Guidelines: stage T1-T2a, PSA<10 ng/ml, ISUP (International Society of Urological Pathologists score)=1 (Gleason score 3+3=6)
not more than 33% cores with adenocarcinoma
Disqualifiers
previous treatment of prostate cancer
other prostatic malignant neoplasms
other oncological diseases
treatment with 5-alfa-reductase inhibitors
Trial design
Treatments tested in this trial
- Not listed
Trial groups
No trial groups listed
Sponsors and collaborators
I.M. Sechenov First Moscow State Medical University
Lead sponsor
Moscow Regional Research and Clinical Institute (MONIKI)
Collaborator
Pirogov Russian National Research Medical University
Collaborator
Source ClinicalTrials.gov